Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3282632 | Clinical Gastroenterology and Hepatology | 2013 | 6 Pages |
Abstract
There is no significant difference in long-term survival between patients with PSC given UDCA (17-23 mg/kg/day) or placebo for 5 years. However, patients who have reduced or normal levels of ALP have longer survival times, regardless of whether they receive UDCA or placebo.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Lina Lindström, Rolf Hultcrantz, Kirsten Muri Boberg, Ingalill Friis-Liby, Annika Bergquist,